Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- EyeGene Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06099613
- Locations
- 🇦🇺
Nucleus Network Pty Ltd- Melbourne, Melbourne, Victoria, Australia
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- EyeGene Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05188469
- Locations
- 🇦🇺
Holdsworth House, Sydney, New South Wales, Australia
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Prevention of Herpes Zoster (HZ)
- Interventions
- Drug: Treatment 2 (EG-HZ-002)Drug: Treatment 1 (EG-HZ-001)Drug: Treatment 3 (EG-HZ-003)Drug: Treatment 4 (EG-HZ-004)Drug: Treatment 5
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- EyeGene Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04210752
- Locations
- 🇦🇺
Q-Pharm Pty Ltd (Nucleus Network), Herston, Queensland, Australia
© Copyright 2025. All Rights Reserved by MedPath